AbbVie shares slip after schizophrenia drug trial misses primary endpoint

AbbVie (NYSE:ABBV ) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US trading.

In a statement, Illinois-based AbbVie said the studies did not show a statistically significant improvement in patients using the medicine, emraclidine, as a once-daily oral monotherapy.

"While we are disappointed with the results, we are continuing to analyze the data to determine next steps," said AbbVie Chief Scientific Officer Roopal Thakkar in a statement.

"We are confident that our innovative pipeline will continue to bring meaningful therapies to patients, and we remain committed to finding better treatments for people living with psychiatric and neurological disorders."

AbbVie currently has approval for its antipsychotic drug Vraylar. It has been pushing to roll out newer medicines for the disease since an $8.7 billion takeover of Cerevel Therapeutics last year.

In October, AbbVie lifted his full-year income forecast, saying its was seeing "momentum" in its operations after third-quarter net revenue topped estimates. The company now expects adjusted profit per share to be between $10.90 to $10.94 in its current fiscal year, up from a prior estimate of $10.67 to $10.87.

In a statement at the time, Chief Executive Robert Michael said the firm has been bolstered by "significant pipeline progress," leading it to have "confidence in the long-term growth outlook." AbbVie has been focusing on building out its pipeline of medications since its blockbuster arthritis drug Humira lost patent protection last year.

Following the announcement on Monday, shares in rival Bristol-Myers Squibb (NYSE:BMY ) rose. The US Food and Drug Administration recently approved the group's schizophrenia drug, Cobenfy. Bristol Myers obtained the drug, which is also known as KarXT, through a $14 billion purchase of Karuna Therapeutics in 2023.

(Reuters contributed reporting.)

Source: Investing.com

Последние публикации
BYD says it sets negotiable price cut targets for suppliers
27.11.2024 - 07:00
Australia stocks higher at close of trade; S&P/ASX 200 up 0.57%
27.11.2024 - 07:00
OpenAI allows employees to sell $1.5 billion stock to SoftBank, CNBC reports
27.11.2024 - 07:00
OpenAI employees to sell $1.5 bln in shares to SoftBank- CNBC
27.11.2024 - 07:00
Asia stocks drift lower; Chinese shares defy Trump tariff threats
27.11.2024 - 06:00
China's BYD sets negotiable price reduction targets for suppliers
27.11.2024 - 06:00
FAA will not require immediate 737 MAX engine action after bird strikes
27.11.2024 - 06:00
Australia moves closer to ban social media for children
27.11.2024 - 06:00
Turkey scales down $23 billion F-16 jet deal with US, minister says
27.11.2024 - 06:00
Taiwan's Foxconn says global manufacturing footprint to shield it from Trump's tariffs
27.11.2024 - 05:00
Trump taps Kevin Hassett to head National Economic Council
27.11.2024 - 04:00
Hyundai Motor to buy back $716 million worth of shares
27.11.2024 - 04:00
Trump tariffs could hurt S&P 500 earnings by ‘few percentage points’- Citi
27.11.2024 - 04:00
Hyundai Motor: Morgan Stanley Overweight, sees resilience against US tariffs
27.11.2024 - 03:00
China courier group S.F. Holding's shares open flat in Hong Kong trading debut
27.11.2024 - 03:00

© Analytic DC. All Rights Reserved.

new
Анализ рынка Как повлият завтра отчет NFP на курс доллара США?